Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.
Upadhyaya SA, Campagne O, Billups CA, Orr BA, Onar-Thomas A, Tatevossian RG, Mostafavi R, Myers JR, Vinitsky A, Moreira DC, Lindsay HB, Kilburn L, Baxter P, Smith A, Crawford JR, Partap S, Bendel AE, Aguilera DG, Nichols KE, Rampersaud E, Ellison DW, Klimo P, Patay Z, Robinson GW, Broniscer A, Stewart CF, Wetmore C, Gajjar A.
Upadhyaya SA, et al. Among authors: wetmore c.
Neuro Oncol. 2023 Feb 14;25(2):386-397. doi: 10.1093/neuonc/noac151.
Neuro Oncol. 2023.
PMID: 35652336
Free PMC article.
Clinical Trial.